The primary end point will be change of sCD14 from Month 3 to Month 12 in the two groups combined (EC and ART <50).

Changes in soluble biomarkers (sCD14, IL-6, D-dimer, hsCRP, sCD163, sTF as well as other relevant markers of inflammation and coagulation) in EC and ART <50 groups treated with ASA or ATV, independently within each group and arm and with grou...

We also wish to investigate the HIV-specific B-cell and T-cell responses in the different subsets of cells in both peripheral blood, aswell as BM and LT of HIV-infected individuals.

In addition, we wish to delineate the precise nature of the immunoregulatory mechanisms and altered homing patterns that contribute to the perturbations in the phenotype and functions of various lymphocyte subsets in peripheral blood versus the ...

The purpose of this project is to determine the relative burden of human immunodeficiency virus (HIV) and/or associated changes in hematopoiesis and immune activation as well as HIV-specific responses in the various subsets of peripheral blood m...

400

All

18 Years and older (Adult, Senior)

NCT00001316

92012592-I-0125

March 18, 1992

November 4, 1999

October 6, 2017

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States

Obtain blood samples for further investigation into the correlation between markers of coagulation, including D-dimer, and markers of platelet function, inflammation, endothelial cell function, and clinical parameters in HIV-infected adults.

375

All

18 Years to 100 Years (Adult, Senior)

NCT00776412

09001309-I-0013

October 17, 2008

October 21, 2008

January 29, 2018

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States

AEs of Grade 3 or higher judged by the Protocol Team to be probably or definitely related to the study drug or that result in permanent discontinuation of study drug due to an AE, judged by the Protocol Team to be at least possibly related to study drug

All AEs of Grade 3 or higher, or that result in permanent discontinuation of study drug

Failure to meet PK target of Cavg greater than or equal to 75 ng/mL

All AEs of Grade 3 or higher or that result in permanent discontinuation of study drug due to toxicity

72

All

Child, Adult, Senior

NCT02778204

IMPAACT 200720734

May 1, 2017

July 31, 2020

July 31, 2020

May 19, 2016

March 13, 2018

University of California, UC San Diego CRS- Mother-Child-Adolescent HIV ProgramLa Jolla, California, United States